Western Radiation Oncology is proud to announce the opening of its newest location in Troy, Michigan, established in close partnership with the Michigan Institute of Urology (MIU), one of the region’s most respected and comprehensive urology groups. This collaboration marks an important step forward in expanding access to advanced, evidence-based prostate cancer treatments across Southeast Michigan.
Located in the Town Center ASC
The new Western Radiation Oncology site is located within the Town Center Ambulatory Surgery Center (ASC), providing patients with a modern, convenient outpatient setting. This integration ensures seamless coordination between urology and radiation oncology teams, and allows patients to access advanced procedures without the complexity of a hospital environment.
Bringing LDR Brachytherapy with Palladium-103 to Troy
At the Town Center ASC in Troy, patients will now have access to Low-Dose Rate (LDR) brachytherapy using Palladium-103 (Pd-103), a highly targeted and proven treatment for localized prostate cancer. Pd-103 brachytherapy delivers radiation directly inside the prostate through tiny radioactive seeds, offering:
- Precise dose delivery that minimizes exposure to surrounding healthy tissue
- Excellent long-term cancer control, particularly for low- and intermediate-risk disease
- A quick outpatient procedure, allowing patients to return home the same day
- Fewer side effects compared to many external radiation therapies
By offering this modality within the Town Center ASC, Western Radiation Oncology and MIU are expanding access to a well-established, minimally invasive treatment in a convenient community setting.